title: Intraarterial catheter-directed thrombolysis: urokinase versus tissue plasminogen activator.
abstract: The purpose of this study was to evaluate the differences between tissue plasminogen activator (TPA) and urokinase (UK) in the management of ischemic limbs. A total of 58 limbs (24 in the TPA group and 34 in the UK group) in 53 patients were studied prospectively. The two groups were based on the surgeon's preference for lytic agent. The dose regimen for UK was 150,000 IU/hr over 1/2 to 2 hr followed by a continuous infusion of 50,000 IU/hr. TPA was given as a 5-mg bolus followed by 1 mg/hr. Both groups received heparin at a rate of 400 IU/hr through the side arm of the arterial sheath. There was no significant difference in efficacy between UK and TPA, but TPA acted faster and had a higher incidence of bleeding complications.
authors.affiliation: Department of Diagnostic Radiology, Hamilton Health Sciences Corporation, McMaster University, Hamilton, Ontario, Canada.
authors.forename: C S
authors.initials: CS
authors.lastname: Cinà
authors.forename: R H
authors.initials: RH
authors.lastname: Goh
authors.forename: J
authors.initials: J
authors.lastname: Chan
authors.forename: B
authors.initials: B
authors.lastname: Kenny
authors.forename: G
authors.initials: G
authors.lastname: Evans
authors.forename: J
authors.initials: J
authors.lastname: Rawlinson
authors.forename: G
authors.initials: G
authors.lastname: Gill
mesh_terms: D000368:Aged; D000792:Angiography; D002406:Catheterization, Peripheral; D005121:Extremities / Q000098:blood supply*; D005260:Female; D006801:Humans; D007511:Ischemia / Q000000981:diagnostic imaging / Q000188:drug therapy*; D008297:Male; D008875:Middle Aged; D010960:Plasminogen Activators / Q000008:administration & dosage* / Q000009:adverse effects; D011446:Prospective Studies; D015912:Thrombolytic Therapy / Q000379:methods*; D010959:Tissue Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects; D017211:Treatment Failure; D014568:Urokinase-Type Plasminogen Activator / Q000008:administration & dosage* / Q000009:adverse effects
chemical_list: D010960:Plasminogen Activators; D010959:Tissue Plasminogen Activator; D014568:Urokinase-Type Plasminogen Activator